Stockreport

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Compelli [Read more]